Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
C-reactive protein (CRP), an acute-phase reactant produced mainly by the liver, is elevated in diabetes, thus contributing to the development and progression of atherosclerosis. However, the molecular mechanism underlying the elevation of CRP in diabetes is not fully understood. Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
Protein levels of the receptor for AGE (RAGE) were analysed by western blots. Gene expression was analysed by quantitative real-time RT-PCR. CRP released into the medium was measured with ELISA. Intracellular formation of reactive oxygen species (ROS) was measured using the fluorescent probe CM-H2DCFDA.
Telmisartan, but not candesartan, another ARB, downregulated RAGE mRNA levels in a dose-dependent manner. Telmisartan decreased basal as well as AGE-induced RAGE protein expression in Hep3B cells. Furthermore, telmisartan dose-dependently inhibited AGE-induced ROS generation and subsequent CRP gene and protein induction in Hep3B cells. GW9662, an inhibitor of PPAR-γ, blocked the inhibitory effects of telmisartan on RAGE expression and its downstream signalling in Hep3B cells.
Our present study indicates a unique beneficial aspect of telmisartan: it may work as an anti-inflammatory agent against AGE by suppressing RAGE expression via PPAR-γ activation in the liver and may play a protective role in vascular injury in diabetes.
- Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299 CrossRef
- Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843 CrossRef
- Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44:6–11 CrossRef
- Benson SC, Pershadsingh HA, Ho CI et al (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002 CrossRef
- Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H (2005) Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 579:4265–4270 CrossRef
- Fukami K, Ueda S, Yamagishi S et al (2004) AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type 1 receptor interaction. Kidney Int 66:2137–2147 CrossRef
- Schupp M, Clemenz M, Gineste R et al (2005) Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54:3442–3452
- Miura Y, Yamamoto N, Tsunekawa S et al (2005) Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care 28:757–758
- Wang LH, Yang XY, Zhang X, Farrar WL (2005) Nuclear receptors as negative modulators of STAT3 in multiple myeloma. Cell Cycle 4:242–245
- Marx N, Walcher D, Ivanova N et al (2004) Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53:2662–2668
- Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
Volume 49, Issue 12 , pp 3094-3099
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Macrovascular disease
- Oxidative stress
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan
- 2. Department of Pathophysiological Science, Faculty of Pharmaceutical Science, Hokuriku University, Kanazawa, Japan